Effects of dendritic cells transfected with full-length wild-type p53 and stimulated by gastric cancer lysates on immune response

World Journal of Gastroenterology

Volumn 10, Issue 17, 2004, Pages 2595-2597

  Sun, Hua Wen ^a   Tang, Qi Bing ^b   Cheng, Yong Jun ^b   Zou, Sheng Qian ^b  

^a WUHAN UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; CELL SURFACE MARKER; CHROMIUM 51; COMPLEMENTARY DNA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN P53; MEMBRANE ANTIGEN; TISSUE EXTRACT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL KILLING; CELL LABELING; CELL LYSATE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE DELIVERY SYSTEM; GENE THERAPY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; IMMUNOSTIMULATION; MOUSE; MOUSE STRAIN; NONHUMAN; STOMACH CANCER; TARGET CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VOLUME; WILD TYPE; ADENOVIRUS; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BAGG ALBINO MOUSE; GENETICS; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; STOMACH TUMOR;

ADENOVIRIDAE; ANIMALS; ANTIGENS, SURFACE; DENDRITIC CELLS; FEMALE; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED BALB C; STOMACH NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TISSUE EXTRACTS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4444381828     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i17.2595     Document Type: Article

References (16)

1. Nikitina EY, Clark JI, Van Beynen J, Chada S, Virmani AK, Carbone DP, Gabrilovich DI. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin Cancer Res 2001; 7: 127-135
2. Nagayama H, Sato K, Morishita M, Uchimaru K, Oyaizu N, Inazawa T, Yamasaki T, Enomoto M, Nakaoka T, Nakamura T, Maekawa T, Yamamoto A, Shimada S, Saida T, Kawakami Y, Asano S, Tani K, Takahashi TA, Yamashita N. Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res 2003; 13: 521-530
3. Adams M, Navabi H, Jasani B, Man S, Fiander A, Evans AS, Donninger C, Mason M. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]: poly [C (12) U] (Ampligen R). Vaccine 2003; 21: 787-790
4. Shimizu K, Thomas EK, Giedlin M, Mule JJ. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res 2001; 61: 2618-2624
5. Eura M, Chikamatsu K, Katsura F, Obata A, Sobao Y, Takiguchi M, Song Y, Appella E, Whiteside TL, DeLeo AB. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. Clin Cancer Res 2000; 6: 979-986
6. Huang HL, Wu BY, You WD, Shen MS, Wang WJ. Influence of dendritic cell infiltration on prognosis and biologic characteristics of progressing gastric cancer. Zhonghua Zhongliu Zazhi 2003; 25: 468-471
7. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Xiangming C, Iwashige H, Aridome K, Hokita S, Aikou T. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Lett 2000; 159: 103-108
8. Weisbart RH, Miller CW, Chan G, Wakelin R, Ferreri K, Koeffler HP. Nuclear delivery of p53 C-terminal peptides into cancer cells using scFv fragments of a monoclonal antibody that penetrates living cells. Cancer Lett 2003; 195: 211-219
9. Asai T, Storkus WJ, Mueller-Berghaus J, Knapp W, DeLeo AB, Chikamatsu K, Whiteside TL. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins. Cancer Immun 2002; 2: 3
10. Portefaix JM, Rio MD, Granier C, Roquet F, Pau B, Navarro-Teulon I. Peptides derived from the two regulatory domains of p53 are recognized by two p53-activating antibodies. Peptides 2003; 24: 339-345
11. Takenobu T, Tomizawa K, Matsushita M, Li ST, Moriwaki A, Lu YF, Matsui H. Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol Cancer Ther 2002; 1: 1043-1049
12. Hoffmann TK, Loftus DJ, Nakano K, Maeurer MJ, Chikamatsu K, Appella E, Whiteside TL, DeLeo AB. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild type sequence p53 (264-272) epitope. J Immunol 2002; 168: 1338-1347
13. Portefaix JM, Fanutti C, Granier C, Crapez E, Perham R, Grenier J, Pau B, Del Rio M. Detection of anti-p53 antibodies by ELISA using p53 synthetic or phage-displayed peptides. J Immunol Methods 2002; 259: 65-75
14. Kanovsky M, Raffo A, Drew L, Rosal R, Do T, Friedman FK, Rubinstein P, Visser J, Robinson R, Brandt-Rauf PW, Michl J, Fine RL, Pincus MR. Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc Natl Acad Sci U S A 2001; 98: 12438-12443
15. Ferries E, Connan F, Pages F, Gaston J, Hagnere AM, Vieillefond A, Thiounn N, Guillet J, Choppin J. Identification of p53 peptides recognized by CD8 (+) T lymphocytes from patients with bladder cancer. Hum Immunol 2001; 62: 791-798
16. Petersen TR, Buus S, Brunak S, Nissen MH, Sherman LA, Claesson MH. Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity. Scand J Immunol 2001; 53: 357-364